Get the Stockscreener App
1.35
7.14%
0.09
Pre-market:
1.35
Pacific Biosciences Of California Inc stock is traded at $1.35, with a volume of 10.42M.
It is up +7.14% in the last 24 hours and down -10.00% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.26
Open:
$1.45
24h Volume:
10.42M
Relative Volume:
1.16
Market Cap:
$405.11M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.90
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+1.50%
1M Performance:
-10.00%
6M Performance:
-13.46%
1Y Performance:
-19.16%
1-Day Range:
$1.2905
$1.51
1-Week Range:
$1.25
$1.51
52-Week Range:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.35 | 414.12M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
134.28 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.14 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
377.58 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.88 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.35 | 46.11B | 5.69B | 4.14B | 577.90M | 6.96 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - sg.finance.yahoo.com
PacBio (PACB) Stock Trades Up, Here Is Why - TradingView
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises - Nasdaq
Pacific Biosciences stock price target raised by Bernstein to $1.70 on clinical uptake - Investing.com Canada
Powered by PacBio: Selected publications from July 2025 - PacBio
Earnings call transcript: Pacific Biosciences Q2 2025 beats revenue expectations, stock surges - Investing.com Canada
Pacific Biosciences of California Q2 2025 Earnings Call Transcript - MarketBeat
Pacific Biosciences shares rise 11.11% premarket after reporting smaller-than-expected Q2 loss and positive trial data. - AInvest
PacBio Narrowed Losses As New Tech And China Deal Paid Off - Finimize
Pacific Biosciences of California Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - sharewise.com
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Pacific Biosciences: Q2 Earnings Snapshot - San Francisco Chronicle
PacBio (NASDAQ:PACB) Delivers Strong Q2 Numbers, Stock Soars - Yahoo Finance
PacBio Announces Second Quarter 2025 Financial Results - GlobeNewswire
PacBio to Present at Upcoming Investor Conferences in August and September 2025 - Quiver Quantitative
PacBio to Present at Upcoming Investor Conferences - Stock Titan
PacBio (PACB) Q2 Earnings Report Preview: What To Look For - Yahoo Finance
Pacific Biosciences of California Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Will Pacific Biosciences of California Inc. Reverse From Oversold ConditionsChart Driven High Reward Trading Setup Presented - beatles.ru
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
PacBio and Collaborators Release Landmark Platinum Pedigree Dataset, Enhancing Genomic Variant Accuracy by 34% With AI Integration - Quiver Quantitative
Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models - Yahoo Finance
How strong is Pacific Biosciences of California Inc. company’s balance sheetGet expert advice on portfolio optimization - Jammu Links News
When is Pacific Biosciences of California Inc. stock expected to show significant growthOutstanding capital returns - Jammu Links News
What catalysts could drive Pacific Biosciences of California Inc. stock higher in 2025Invest smarter with expert trading signals - Jammu Links News
Should I hold or sell Pacific Biosciences of California Inc. stock in 2025Superior risk-adjusted returns - Jammu Links News
How does Pacific Biosciences of California Inc. generate profit in a changing economyAchieve rapid wealth accumulation with smart picks - Jammu Links News
What institutional investors are buying Pacific Biosciences of California Inc. stockUnprecedented profits - Jammu Links News
What are Pacific Biosciences of California Inc. company’s key revenue driversBuild a diversified portfolio for steady growth - Jammu Links News
What is Pacific Biosciences of California Inc. company’s growth strategyExponential return rates - Jammu Links News
Is Pacific Biosciences of California Inc. a growth stock or a value stockAccess high-yield investment alerts now - Jammu Links News
What are analysts’ price targets for Pacific Biosciences of California Inc. in the next 12 monthsLightning-fast growth - Jammu Links News
Published on: 2025-08-03 06:22:09 - Jammu Links News
What is the dividend policy of Pacific Biosciences of California Inc. stockBuild a portfolio that delivers consistent profits - Jammu Links News
How Pacific Biosciences of California Inc. stock performs during market volatilityLow Risk Picks for Daily Trading Released - beatles.ru
Options Data Show Bullish Bias in Pacific Biosciences of California Inc.Conservative Long Term Growth Plans Under Review - metal.it
Does Pacific Biosciences of California Inc. stock perform well during market downturnsFinancial News Target Finder For Smart Trading - jammulinksnews.com
Customer success story: How Dr. Ibrahim Bitar is doubling his research impact while leading the future of European genomics from the Czech Republic - PacBio
Pacific Biosciences (PACB) Jumps 6.5% Ahead of Earnings - MSN
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
What makes Pacific Biosciences of California Inc. stock price move sharplyPattern Breakout Entry Stock Forecast in Focus - metal.it
Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
PacBio, 10x Genomics, QuidelOrtho, STAAR Surgical, and Clover Health Stocks Trade Down, What You Need To Know - Yahoo Finance
Pacific Biosciences Soars 6.5% Pre-Earnings Amid Restructuring Hopes - AInvest
Even after rising 13% this past week, Pacific Biosciences of California (NASDAQ:PACB) shareholders are still down 63% over the past three years - Yahoo Finance
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing - MarketScreener
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):